# Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

> **NCT07523529** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Unresectable
- Metastatic

## Interventions

- **BIOLOGICAL:** Autologous dual-target CAR-T cells selected from the predefined target library.
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07523529
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-04-14
- **Final completion:** 2028-03-17
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07523529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07523529, "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07523529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*